Learn more about whether LeMaitre Vascular, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

Short interest in Lantheus Holdings Inc (NASDAQ:LNTH) decreased during the last reporting period, falling from 6.46M to 6.42M. This put 12.34% of the company's publicly available shares short.

operations - the R13.9 billion disposal of LMI to Lantheus Holdings announced in January was on track and was expected to be completed during the second half. Overall paid patient days (PPDs ...

Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The company’s 50-day moving average price is $93.32 and its two-hundred day moving average price is $95.80.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The stock has a market cap of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38. Want More Great Investing ...

Below is Validea's guru fundamental report for LANTHEUS HOLDINGS INC (LNTH). Of the 22 guru strategies we follow, LNTH rates highest using our Twin Momentum Investor model based on the published ...

Here's a peek at a few of the choices from the screener. Overview: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling ...

BEDFORD, Mass. - Lantheus Holdings, Inc. (NASDAQ: LNTH), a leader in the radiopharmaceutical industry, announced today the completion of its acquisition of Evergreen Theragnostics, Inc., a ...